@VickersBiostats Great point. I also meet a lot of folks who don’t know the definition of a high quality PLND which is essential to maximize the benefits
English
Michael Abern
40 posts
Michael Abern
@michaelabern
Associate Professor of Urologic Oncology at Duke Cancer Institute
Durham, NC Katılım Mayıs 2009
116 Takip Edilen255 Takipçiler
Across urology, the message is clear. Everyone has ignored the RCT evidence and the associated decision analysis pubmed.ncbi.nlm.nih.gov/41105637/ on ePLND. At AUA I had numerous conversations with folks presenting posters on PLND who hadn't even read the ePLND RCT.
DR CARVAJAL@RomanCarvajal
At #AUA2026, the message was clear: 📌 ePLND provides staging information, but its therapeutic benefit remains uncertain. 📌 RCTs have not shown consistent improvements in BCR outcomes. 📌 PSMA PET/CT has a high NPV (~96%) and may safely avoid unnecessary PLND in intermediate-risk patients with negative scans. 📌 Morbidity is not negligible: lymphedema, DVT/PE, and potential overtreatment. 📌 Up to 47% of nodal metastases may even lie outside the standard ePLND template. The question is no longer “PLND yes or no?” 👉 It’s about smarter selection using PSMA PET, nomograms, and individualized risk assessment. #ProstateCancer #PSMAPET
English
Michael Abern retweetledi
Excited to be presenting at #AUA26 and catching up with colleagues and friends!
@michaelabern @DukeCancer @Hoomandjaladat @siadaneshmand @AmerUrological
English
Michael Abern retweetledi
#AUA26 @UroOnc session - 3 papers in the past year that influenced my practice: @ClintonTim highlights our @EurUrolFocus paper on the outcomes of rob PC-RPLND for testicular cancer @Hoomandjaladat
English
Michael Abern retweetledi
💡Promising work from @alirezaghoreifi and @Hoomandjaladat at #AUA2026 evaluating Bladder CARE as a non-invasive tool for UTUC diagnosis and surveillance.
🧬 Encouraging results highlighting the potential of urine-based epigenetic biomarkers in upper tract disease.
English
Michael Abern retweetledi
Check out the data from PSMAfore biomarker analysis: Huge prognostic significance in baseline and 6-week on treatment ctDNA levels and outcomes. Adds to PSA 50 response as well. Could guide future management in this earlier disease setting. @DukeCancer #GU25
English
Our @DukeUrology team looking fresh after completing the Shakori40 trail ultra marathon relay! Best quote of the day : “Perfect day aside from all of the running “ 😅
English
Our oncologic surgeons at @DukeUrology are looking forward to the SUO annual meeting. We are excited to discuss our fellowship program with interested resident applicants. DM me or @AnkeetShahMD to set up a meeting at SUO…
English
@ChapinMD Difference between palpable cT3 and MRI “capsular abutment or bulging” cT3. I’m reluctant to label cT3 based on MR alone .
English
Case of the day.
51 yo with cT3aN0M0 on CT/BS/MRI, GG5, PSA 12, IIEF-23, AUA-SI of 6
PSMA PET w/left obturator 6mm LN with SUV of 7, Liver at 8.
Treatment choice for uros:(separate poll for Rad/Oncs)
English
@DukeHealth @DukeSurgery @DukeUrology @DukeHospital @DukeGUCancer I’m grateful to our clinical research and robotic surgery team for getting us started! Just the beginning….
English
Congratulations to Dr. Michael Abern & colleagues for this technological milestone.
@DukeSurgery | @DukeUrology | @DukeHospital | @DukeGUCancer
Medtronic@Medtronic
With the first patient enrolled, our U.S. clinical trial for the Hugo™ robotic-assisted surgery system is officially underway. medtronic.co/3PytR0P
English
@BrantInman 2: assuming you mean phase 3 based on promising phase 1/2
English
@BrantInman @DukeGUCancer @AmCollSurgeons @CMSGov Yes. Trying to limit outpatient radiology but balance with risk. Staging and surveillance and expected progression can be gray areas. Most agree on what is emergent.
English
English
@BrantInman @DukeGUCancer @AmCollSurgeons @CMSGov Thanks. We put together a surgical acuity matrix for all urologic surgery. My next challenge is trying to categorize cancer imaging. Have you guys tackled it yet ?
English
@RealProstateDoc If it’s clear cell and the distal pancreas or SMA are involved could try to downstage with IOT (#3). If not just resect
English
Twitter Tumor Board
Healthy 63 yo. Remote R. nephrectomy adrenalectomy for RCC. Remote lung mets x 2 Rx with metastectomy plus INF-a/IL-2. NOW THIS - symptomatic.
Assuming Bx+ RCC, what would u do?
1. Resection
2. Systemic therapy
3. Systemic therapy and Sx if response
English
Excellent visiting professor lecture by Dr Skinner on the nuances of the AUA MIBC guidelines @UICUrol
English
@PatrickSelph @SocietyGURS @SUO_YUO yes - that’s what I do. however, I don’t have data to support it. perhaps a higher parastomal hernia rate?
English
What’s been your experience with ileal conduit through fascia only on same side of VRAM during pelvic exent? Do you put both ostomies in same side to avoid conduit through side without muscle? @SocietyGURS @SUO_YUO
English
Michael Abern retweetledi
#BallingforHealth this morning, @DrWinnUIC encourages young men to talk with their families about their health this holiday season. #uic3on3 #menshealth @djpatxkl @thisisUIC @michaelabern @UICUrol @UIHealth pic.twitter.com/hlbIFPtwVk
English
Michael Abern retweetledi
So close to 500 followers - currently sitting at 496.
Do follow us for updates on the latest research papers on prostate cancer and prostatic diseases
English